• Dual primary endpoints were progression-free survival by blinded independent review for the combination vs sorafenib in the first 372 patients randomly assigned to these two arms (ITT [intention-to-treat] analysis) and overall survival for the combination vs sorafenib in all randomly assigned patients (ITT analysis). (ascopost.com)
  • Progression-related endpoints (such as time to progression or progression-free survival) and time to death are common endpoints in cancer clinical trials. (eur.nl)
  • It is of interest to study the link between progression-related endpoints and time to death (e.g. to evaluate the degree of surrogacy). (eur.nl)
  • However, current methods ignore some aspects of the definitions of progression-related endpoints. (eur.nl)
  • Sequential primary endpoints were progression-free survival on central blinded analysis and overall survival. (ascopost.com)
  • TOKYO & BASKING RIDGE, N.J.-(BUSINESS WIRE)-Topline results from the primary analysis of the ongoing DESTINY-PanTumor02 phase 2 trial showed ENHERTU ® (trastuzumab deruxtecan) demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients across multiple HER2 expressing advanced solid tumors, two secondary endpoints of the trial. (biotech-365.com)
  • The weighted linear regression model showed a strong positive association between the two survival endpoints. (bmj.com)
  • Patients who received panitumumab every two weeks showed a 46 percent decrease in tumor progression rate versus those who received best supportive care alone (p less than 0.000 000 001). (amgen.com)
  • Therefore, the early prediction of tumor progression in patients who receive EGFR‑ TKIs can facilitate patient management and development of treat‑ ment strategies. (sagepub.com)
  • The personalized PFS curves can help make accurate and individualized predictions of tumor progression. (sagepub.com)
  • Factors predictive of tumor progression included age greater than 65 years (hazard ratio [HR] 2.36, 95% CI 1.30-4.29, p = 0.005), prior history of radiotherapy (HR 5.19, 95% CI 1.69-15.94, p = 0.004), and increasing tumor volume (HR 1.05, 95% CI 1.01-1.08, p = 0.005). (thejns.org)
  • Rarely, additional procedures may be required for hydrocephalus or tumor progression. (thejns.org)
  • CONCLUSION: After tumor progression with EGFR TKI therapy and PBC in patients with EGFR-mutated NSCLC, HER3-DXd once every 3 weeks demonstrated clinically meaningful efficacy with durable responses, including in CNS metastases. (bvsalud.org)
  • The phase III COSMIC-312 study has met its primary endpoint, showing a significant improvement in progression-free survival with cabozantinib plus atezolizumab compared with sorafenib in treatment-naive hepatocellular carcinoma (HCC), investigators reported at a European Society for Medical Oncology (ESMO) Virtual Plenary Session in November 2021. (ascopost.com)
  • The Phase III DUO-E study has achieved very positive results Resumé (durvalumab) in combination with platinum-based chemotherapy followed by either Resumé Plus Lynparz (be improved) Lub Resumé as maintenance therapy alone, both showed a statistically significant and clinically significant improvement in progression-free survival (PFS) compared with standard chemotherapy in patients with newly diagnosed advanced or recurrent endometrial cancer. (mydrai.biz)
  • Participants were randomly assigned to receive carboplatin-paclitaxel (control arm) for six cycles with or without intravenous trastuzumab (experimental arm) until progression or unacceptable toxicity. (nih.gov)
  • Aetna considers continuation of carfilzomib (Kyprolis) therapy medically necessary for members requesting reauthorization for an indication listed in Section I when there is no evidence of unacceptable toxicity or disease progression while on the current regimen. (aetna.com)
  • The TROPION-Lung01 results demonstrate for the first time that an antibody drug conjugate can delay disease progression or death for longer than conventional chemotherapy in patients with advanced non-small cell lung cancer. (businesswire.com)
  • Margetuximab plus chemotherapy improved progression-free survival vs trastuzumab plus chemotherapy in patients with pretreated ERBB2-positive advanced breast cancer. (ascopost.com)
  • BUSINESS WIRE )--Positive results from the pivotal TROPION-Lung01 Phase III trial showed that datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant improvement for the primary endpoint of progression-free survival (PFS) compared to docetaxel, the current standard of care, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy. (businesswire.com)
  • The key secondary endpoint was progression-free survival for the single agents cabozantinib vs sorafenib. (ascopost.com)
  • The risk of disease progression was reduced significantly by 37%, but no significant differences were observed for the primary overall survival endpoint in the ITT population. (ascopost.com)
  • Event-free survival is commonly used in studies of neoadjuvant treatments - therapies delivered before the main treatment to help shrink the tumor or eliminate any cancer cells that have spread - and as a primary trial endpoint for potentially curative therapies. (medscape.com)
  • This correlation between progression-free survival and overall survival after primary treatment for ovarian cancer highlights the validity of progression-free survival as a primary endpoint. (bmj.com)
  • Overall survival is regarded as the gold standard endpoint in cancer clinical trials but often requires large, expensive, and time-consuming trials to demonstrate a benefit, compared with trials utilizing progression-free survival as a primary endpoint. (bmj.com)
  • The trial met its primary endpoint, showing superior overall survival (OS) with Opdivo plus Yervoy versus chemotherapy (pemetrexed and cisplatin or carboplatin) in all randomized patients. (pharmiweb.com)
  • Introduction: Radiographic progression-free survival (rPFS) by Prostate Cancer Working Group (PCWG) criteria is a radiographic endpoint. (lu.se)
  • Similarly, "disease-free survival" is the length of time after patients have received treatment and have no detectable disease. (wikipedia.org)
  • However, no randomized or nonrandomized study using 3 months of NADT has shown any statistically significant benefit in terms of overall and disease-free survival. (medscape.com)
  • Disease-free survival is defined as the average length of time from the start of treatment until the cancer returns. (medscape.com)
  • Although disease-free survival and PFS seem quite similar, PFS is typically used in more advanced disease settings, while disease-free survival is typically used as a surrogate for cure . (medscape.com)
  • This approval is based on results from the Phase 3 KEYNOTE-590 trial, in which KEYTRUDA plus 5-fluorouracil (5-FU) and cisplatin demonstrated statistically significant improvements in overall survival (OS) and progression-free survival (PFS) compared with 5-FU and cisplatin alone in all pre-specified study populations. (merck.com)
  • We identify a new measure of microenvironmental diversity derived from Shannon entropy that is highly predictive of poor overall ( p = 0.002, HR = 3.18, 95% CI = 1.51-6.68) and progression-free survival ( p = 0.0036, HR = 2.83, 95% CI = 1.41-5.7), independent of and stronger than clinical variables, subtype stratifications based on single cell types alone and number of sites. (oncotarget.com)
  • Conclusions Median progression-free survival was predictive of median overall survival. (bmj.com)
  • Assessment of serum IL-10 levels in HCV patients may provide a possible predictive marker for disease progression. (who.int)
  • The European Commission's approval of KEYTRUDA plus chemotherapy for the treatment of certain patients with esophageal and HER2-negative GEJ cancer provides a new option in the first-line setting that has shown significant improvements in progression-free and overall survival. (merck.com)
  • Primary outcomes included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). (hindawi.com)
  • Although EGFR TKI therapy has shown superior outcomes for objective response rate, progression-free survival, quality of life, and safety profiles, the majority of patients develop resistance most commonly due to the T790M mutation found on exon 20 of the EGFR gene. (oncologynurseadvisor.com)
  • Those with ≥1 result prior and received recommended therapy had a longer median PFS and lower risk of progression. (ispor.org)
  • Obinutuzumab plus bendamustine provides a new treatment option that can be used after relapse to significantly reduce the risk of progression or death," Dr Horning said in a statement. (medscape.com)
  • PFS has also become a popular surrogate for overall survival because fewer patients are needed in the trial setting and PFS can be measured more quickly. (medscape.com)
  • However, the use of PFS remains controversial because a growing body of evidence indicates it is often a poor surrogate for overall survival. (medscape.com)
  • We investigated whether tumor response, disease control, progression-free survival (PFS), or time to progression (TTP) could be considered a valid surrogate for OS to assess the benefits of first-line therapies for patients with metastatic breast cancer. (eur.nl)
  • It is encouraging that progression-free survival benefits were consistent across all clinically relevant subgroups, and that sotorasib response rates were more than double compared to docetaxel response rates. (headlinesoftoday.com)
  • If real disease progression can be defined in terms of marginal PFT thresholds, then their inclusion in clinical decision-making and in therapeutic trial end-points would allow increased recognition of clinically relevant disease behaviour. (ersjournals.com)
  • In the CheckMate -743 trial, this dual immunotherapy combination demonstrated a clinically meaningful improvement in survival over the standard of care, with 41% of patients who received Opdivo plus Yervoy still alive at two years, compared to only 27% with chemotherapy," said Abderrahim Oukessou, M.D., vice president, thoracic cancers development lead, Bristol Myers Squibb. (pharmiweb.com)
  • The rate (75 percent) and timing (median 7.0 weeks) of crossover from the BSC alone arm to receiving panitumumab, and the anti-tumor activity observed after crossover, likely confounded the ability to demonstrate a treatment effect on overall survival (Hazard ratio = 0.93). (amgen.com)
  • Median progression-free survival at that time was 5.8 months (95% confidence interval [CI] = 5.5-7.0 months) in the margetuximab group vs 4.9 months (95% CI = 4.2-5.6 months) in the trastuzumab group (hazard ratio [HR] = 0.76, 95% CI = 0.59-0.98, P = .03). (ascopost.com)
  • The improvement in progression-free survival observed with datopotamab deruxtecan, particularly in patients with non-squamous tumors, and the improved tolerability of this antibody drug conjugate compared to docetaxel, represent a meaningful advance for patients with lung cancer. (businesswire.com)
  • An antibody-drug conjugate (ADC) targeting HER2 significantly slowed progression of previously treated metastatic breast cancer versus chemotherapy, a multinational randomized trial showed. (medpagetoday.com)
  • The tumor microenvironment is pivotal in influencing cancer progression and metastasis. (oncotarget.com)
  • Adjuvant therapy was also superior with respect to biochemical failure, distant metastasis, and metastasis-free survival. (medscape.com)
  • Among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, daratumumab combined with bortezomib, melphalan, and prednisone resulted in a lower risk of disease progression or death than the same regimen without daratumumab. (nih.gov)
  • 103. Relapsed or refractory disease, as defined by the following: - Disease progression after last regimen, or - Failure to achieve a PR or CR to the last regimen 104. (who.int)
  • With NADT prior to RP, the intent is to eradicate malignant androgen-dependent cells, in the hope that sufficient tumor regression will permit complete resection of residual prostate cancer, improving pathologic outcome and survival. (medscape.com)
  • Studies find that new cancer drugs approved by the U.S. Food and Drug Administration improve progression-free survival by a median of 2 to 3 months depending on the sample and analyzed time period: 2.5 months, 2.70 months, 3.30 months. (wikipedia.org)
  • For example, after six months (week 24) approximately four times as many panitumumab-treated patients were alive and progression-free (18 percent versus five percent with BSC alone). (amgen.com)
  • The primary progression-free analysis was triggered by the last trial randomization in October 2018, with a median follow-up of 2.8 months. (ascopost.com)
  • Median investigator-assessed progression-free survival was 5.6 vs 4.2 months (HR = 0.70, 95% CI = 0.56-0.87, P = .001). (ascopost.com)
  • At the second planned interim analysis of overall survival in Septem ber 2019, the median follow-up for overall survival was 15.6 months. (ascopost.com)
  • Median overall survival was 21.6 months (95% CI = 18.9-24.1 months) in the margetuximab group vs 19.8 months (95% CI = 17.5-22.3 months) in the trastuzumab group (HR = 0.89, 95% CI = 0.69-1.13, P = .33). (ascopost.com)
  • Survival is variable, depending on the different prognostic factors, ranging from months to more than 10 years. (scielo.br)
  • Median progression-free survival (PFS) improved from 4.9 months with investigator's choice of chemotherapy to 7.0 months with trastuzumab duocarmazine (SYD985). (medpagetoday.com)
  • A preliminary analysis of overall survival (OS) showed a trend in favor of the ADC (20.4 vs 16.3 months). (medpagetoday.com)
  • The median overall survival among these patients was 63 months. (medscape.com)
  • The first randomized study in malignant pheochromocytoma and paraganglioma (MPP) has found that sunitinib prolongs progression-free survival (PFS) by more than five months. (news-medical.net)
  • 0001). Median progression-free survival was not reached in the obinutuzumab group, but was 13.8 months in the group receiving bendamustine alone. (medscape.com)
  • Median progression-free survival for all patients was 18.8 months but had not been reached for the 19 responders. (sciencedaily.com)
  • Median response duration for responders was 20.2 months, with only seven having disease progression as of May 2013. (sciencedaily.com)
  • Lynparz or placebo until disease progression for 24 months. (mydrai.biz)
  • Several series have shown an increase in median survival duration with postoperative radiation, from 8 months with surgery alone to more than 19 months. (medscape.com)
  • Researchers found that with just the standard chemotherapy combination of carboplatin and paclitaxel/nab-paclitaxel, median overall survival for metastatic NSCLC reached about 11.3 months. (mesothelioma.com)
  • When they paired chemotherapy with Keytruda®, follow-ups showed overall survival extended to 15.9 months on average across all the lung cancer patient subgroups in the trial, including in those with low PD-L1 expression. (mesothelioma.com)
  • In addition, a single injection of CAN-3110 in patients with recurrent high-grade glioma resulted in a median overall survival of 11.6 months. (tmcnet.com)
  • Median overall survival for these patients, if untreated, is approximately 3 months. (medscape.com)
  • [ 1 ] Because this is typically a late complication of systemic disease, melanoma-related brain metastases have been associated with significant neurologic morbidity and a poor median overall survival, with treatment, of approximately 9 months. (medscape.com)
  • and median overall survival, 11.9 months. (bvsalud.org)
  • Panitumumab reduced the rate of disease progression by approximately half compared to best supportive care alone in these heavily pre-treated patients," said Marc Peeters, M.D., Ph.D., coordinator of Digestive Oncology Unit, University Hospital Ghent, and one of the study's lead investigators. (amgen.com)
  • Professional oncology social workers provide free emotional and practical support for people with cancer, caregivers, loved ones and the bereaved. (cancercare.org)
  • In oncology studies, overall survival reflects how many people receiving a particular treatment were still alive at a certain timepoint or how long the typical person receiving the treatment lived. (medscape.com)
  • Shannon N. Westin, professor of gynecologic oncology and reproductive medicine at the University of Texas MD Anderson Cancer Center and principal investigator of the DUO-E study, said, "These exciting data show that durvalumab immunotherapy can reduce disease progression in endometrial patients and significantly delay cancer. (mydrai.biz)
  • The progression-free survival and overall survival results for ENHERTU alongside the continued robust and durable tumor responses seen with further follow-up underscore the potential value of this important medicine for patients with HER2 expressing cancers who currently have no targeted treatment options," said Cristian Massacesi, MD, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca. (biotech-365.com)
  • We have seen few advances over the last three decades that have improved historically poor survival outcomes for patients with esophageal cancer," said Professor Antoine Adenis, Department of Medical Oncology, Montpellier Cancer Institute, France. (merck.com)
  • PFS improvements do not always result in corresponding improvements in overall survival, and the control of the disease may come at the biological expense of side effects from the treatment itself. (wikipedia.org)
  • Panitumumab treatment also showed a clinical benefit in the patients crossing over from the BSC arm, despite their disease progression. (amgen.com)
  • Studies addressing the effect of timing of RT on survival suffer from considerable bias, such as inhomogeneous patient populations, inhomogenous treatment protocols or disregard for tumor location, EOR, and RTV. (springer.com)
  • We retrospectively analyzed clinical characteristics, response to treatment and survival of 282 patients with active newly-diagnosed multiple myeloma, comparing results between patients younger and older than 65 years. (scielo.br)
  • The aims of the present study were to describe clinical features at diagnosis, response to treatment and survival in 282 patients with active newly-diagnosed MM (NDMM) and compare outcomes between patients younger and older than 65 years. (scielo.br)
  • Characteristics of the disease at diagnosis, first-line treatment and response, date of progression or death and cause of mortality were detailed. (scielo.br)
  • Treatment with SYD985 significantly improved progression-free survival in comparison with standard physician's choice treatment in patients with HER2-positive metastatic breast cancer with two prior regimens or T-DM1 (trastuzumab emtansine, Kadcyla) in the metastatic setting," she said in conclusion. (medpagetoday.com)
  • As such, overall survival remains the gold standard for assessing the effectiveness of a cancer therapy or treatment plan, which may involve a new drug or drug combination, radiation, or surgery. (medscape.com)
  • Event-free survival measures how long people in a clinical trial remain free of certain major 'events,' such as disease progression, relapse, treatment discontinuation, or death. (medscape.com)
  • In situations where a cancer has spread to new organs and eradicating the tumor cells is no longer possible, the goal of treatment may be to halt further growth or disease progression. (medscape.com)
  • Time to progression measures the length of time before a person's cancer escapes the treatment and starts to grow again. (medscape.com)
  • Time to next treatment is largely useful in studies of long-term, incurable cancers that need many drugs in sequence to prolong survival. (medscape.com)
  • ADR: IPSEY) today announced three-year minimum, 44-month median, follow-up results from the Phase III CheckMate -9ER trial showing that Cabometyx® (cabozantinib) in combination with nivolumab provides survival and response rate benefits after three-years in the first-line treatment of advanced renal cell carcinoma (aRCC), compared to sunitinib. (news-medical.net)
  • Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo) plus ipilimumab (Yervoy) experienced longer treatment-free survival (TFS) over a 42-month period than patients who received the targeted therapy sunitinib (Sutent), regardless of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group, according to new analysis of the CheckMate-214 clinical trial. (news-medical.net)
  • The fact that this approach stalled cancer progression by more than a year will be good news to patients, who urgently need additional treatment options," she added. (medscape.com)
  • The primary end point was progression-free survival, which was assessed for differences between treatment arms via one-sided log-rank tests. (nih.gov)
  • The research team examined blood samples and tumor biopsies to identify possible risk factors and genes that might indicate response to treatment and survival. (sciencedaily.com)
  • Gene expression analysis of tumor samples from 18 patients before treatment showed that progression-free survival increased for patients when their gene signature included genes that are highly active during T cell response or repressed in regulatory T cells that dampen T cell activation," said Eric Davis, M.D., associate professor of Lymphoma/Myeloma and co-senior author of the paper. (sciencedaily.com)
  • We proposed a deep learning approach based on both quantitative computed tomography (CT ) characteristics and clinical data to predict progression‑free survival (PFS) in patients with advanced NSCLC after EGFR‑ TKI treatment. (sagepub.com)
  • The DeepSurv models for the progression risk stratification of EGFR‑ TKI treatment were proposed based on CT radiomic and clinical features from 270 stage IIIB‑IV EGFR‑mutant NSCLC patients. (sagepub.com)
  • ONIVYDE is a topoisomerase inhibitor indicated, in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. (nih.gov)
  • A prospective, multicenter study showed a significant survival benefit in the PDT treatment group. (medscape.com)
  • With the success of KEYNOTE-407 and other trials, researchers hope the same methodology can be applied to other cancers like mesothelioma, potentially updating the standard treatment options and improving survival. (mesothelioma.com)
  • With the European Commission approval of this dual immunotherapy combination, patients and doctors will now have a new treatment option that has shown significant improvements in survival to manage this resistant disease. (pharmiweb.com)
  • The data demonstrated evidence of local and systemic anti-tumor activity in patients with inadequate response to previous immune checkpoint inhibitor (ICI) treatment and showed a disease control rate of 77 percent (20/26) in patients entering the trial with disease progression despite ICI treatment. (tmcnet.com)
  • Treatment continues for 6 courses in the absence of disease progression. (knowcancer.com)
  • With these advances, early trials have demonstrated improved overall survival in patients with brain metastases who receive these therapies either as single agents or as part of multimodality treatment regimens. (medscape.com)
  • These encouraging results deserve further investigation to determine their impact on overall survival in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu. (nih.gov)
  • The overall survival demonstrated by ENHERTU in these patients is a significant step forward in the potential to advance current standards of care and offer new options for patients with HER2 expressing cancers. (biotech-365.com)
  • Though Keytruda® and other immunotherapies have yet to be FDA approved for the rare cancer, these therapies have already shown success in various clinical trials in extending survival for numerous patients, including those with classical Hodgkin lymphoma, head and neck squamous cell carcinoma (HNSCC), and certain advanced cancers like melanoma and metastatic urothelial carcinoma. (mesothelioma.com)
  • THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 3, 2006--Amgen (Nasdaq:AMGN), the world's largest biotechnology company, today announced pivotal Phase 3 results demonstrating that panitumumab significantly improved progression-free survival and disease control (response rate and stable disease) compared to best supportive care (BSC) in metastatic colorectal cancer patients who had failed standard chemotherapy. (amgen.com)
  • Twice as many panitumumab-treated patients were alive and progression-free at week 32 (10 percent versus four percent with BSC alone). (amgen.com)
  • Improvements in progression-free survival and disease control also occurred regardless of age, sex, primary tumor location (colon versus rectum), or performance status. (amgen.com)
  • The 15-year progression-free survival was 36% with adjuvant therapy versus 29% with neoadjuvant therapy ( P = 0.01). (medscape.com)
  • However, the NCCN notes that androgen deprivation therapy before, during, and/or after radiation prolongs survival in selected patients who are receiving radiation therapy only. (medscape.com)
  • Conclusion Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival. (nih.gov)
  • The bacteriostatic water for injection is a colourless, transparent solution, free of visible particles and is intended to use for the reconstitution of [BT-ON014 trade name] to yield a multi-dose solution containing 21 mg/mL trastuzumab at a pH of approximately 6.0. (who.int)
  • Similarity and diversity of the tumor microenvironment in multiple metastases: critical implications for overall and progression-free survival of high-grade. (oncotarget.com)
  • [ 2 ] Factors that predict survival include age, performance status, and the number of brain metastases, which are summarized as the melanoma-specific graded prognostic assessment. (medscape.com)
  • Panitumumab improved progression-free survival and response rate regardless of the measured level or intensity of EGFr staining. (amgen.com)
  • Approximately half of the patients with EGFR‑mutated NSCLC are treated with EGFR‑ TKIs and develop disease progression within 1 year. (sagepub.com)
  • The definition of "progression" generally involves imaging techniques (plain radiograms, CT scans, MRI, PET scans, ultrasounds) or other aspects: biochemical progression may be defined on the basis of an increase in a tumor marker (such as CA125 for epithelial ovarian cancer or PSA for prostate cancer). (wikipedia.org)
  • Approximately 75% of patients have metastatic diseases at diagnosis [ 15 ], and survival rate for International Federation of Gynecology and Obstetrics (FIGO) stage III-IV ovarian cancer ranges from 25% to 37% [ 43 ]. (oncotarget.com)
  • The vast majority (70-80%) of ovarian cancer deaths are from high-grade serous carcinoma (HGSOC) with hardly any change in overall survival in the past years [ 6 ]. (oncotarget.com)
  • For example, in this ovarian cancer study , rucaparib was associated with improved PFS compared with chemotherapy but worse overall survival. (medscape.com)
  • Objectives This analysis aimed to better define the relationship between progression-free survival and overall survival in adult patients with ovarian cancer (including fallopian tube or primary peritoneal cancer) following primary cytoreductive surgery or interval cytoreductive surgery. (bmj.com)
  • In this phase 3 trial, we randomly assigned 706 patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation to receive nine cycles of bortezomib, melphalan, and prednisone either alone (control group) or with daratumumab (daratumumab group) until disease progression. (nih.gov)
  • Those concerns regarding prostate cancer progression have led to a renewed interest in the use of NADT prior to RP. (medscape.com)
  • Help us continue to provide free programs and services to anyone affected by cancer. (cancercare.org)
  • Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial. (news-medical.net)
  • Lung cancer is the most common malignant neoplastic In this study, we proposed a deep learning-based disease worldwide and is categorized into small cell lung approach to assess the personalized probability of tumor cancer and non-small cell lung cancer (NSCLC), caus- progression in patients who had advanced NSCLC with ing nearly 2 million deaths globally each year [1]. (sagepub.com)
  • 201. History of malignancy other than non-melanomatous skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) unless disease free for at least 3 years. (who.int)
  • Progression may also be due to the appearance of a new lesion or to unequivocal progression in other lesions, such as an increase in size or the lesions spreading to nearby tissues. (wikipedia.org)
  • In a study of 1636 patients with unresectable localized intrahepatic cholangiocarcinoma, the addition of radiation to chemotherapy was associated with an improvement in overall survival. (medscape.com)
  • The pivotal Phase 3 study enrolled over 500 patients and demonstrated an improvement in progression free survival (PFS) for patients treated with YONDELIS. (prnewswire.com)
  • Purpose Overall survival (OS) can be observed only after prolonged follow-up, and any potential effect of first-line therapies on OS may be confounded by the effects of subsequent therapy. (eur.nl)
  • METHODS: Adults with disease progression on previous therapies were eligible. (bvsalud.org)
  • Most data regarding the impact of age on survival mainly come from clinical trials developed before the current therapy choices were in use. (scielo.br)
  • Many advanced NSCLC clinical trials are also often applied to mesothelioma, as the disease progressions are rather similar. (mesothelioma.com)
  • Our hypothesis was that a marginal change in lung function parameters would predict survival and allow a more sensitive signal to be used in clinical decision-making and therapeutic trials. (ersjournals.com)
  • Progression-free survival also improved in both trials. (mesothelioma.com)
  • Dr. Kelley presented the final primary progression-free survival analysis and the interim analyses for overall survival, as well as the interim analysis of progression-free survival for the comparison of cabozantinib and sorafenib as single agents. (ascopost.com)
  • Prespecified interim analyses of overall survival for cabozantinib/atezolizumab vs sorafenib and progression-free survival for cabozantinib vs sorafenib were performed at the primary progression-free survival analysis. (ascopost.com)
  • Kaplan-Meier and Cox regression analyses were used to compare progression free survival (PFS) and overall survival (OS) between the groups. (springer.com)
  • For analyses of the relationship between overall survival and progression-free survival, 21 studies were eligible. (bmj.com)
  • She explained the rationale for combining cabozantinib and atezolizumab: cabozantinib is a standard of care after first-line sorafenib, having been shown to improve overall survival and progression-free survival vs placebo in that setting. (ascopost.com)
  • An interim analysis of overall survival between the two groups was similar. (amgen.com)
  • A study of 66 patients with unresectable intrahepatic cholangiocarcinoma treated with hypofractionated radiation therapy reported 2-year outcomes of 84% local control and 58% overall survival. (medscape.com)
  • Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy. (who.int)
  • Time to progression (TTP) does not count patients who die from other causes but is otherwise a close equivalent to PFS (unless there are many such events). (wikipedia.org)
  • A significantly higher proportion of patients were alive and free of disease progression on panitumumab at all of the scheduled time points through week 32. (amgen.com)
  • Overall survival (OS) data were immature at the time of this analysis, but a favorable trend was observed for both regimens. (mydrai.biz)
  • aBSI increase in bone disease was assessed from baseline scan to time-to-progression (per PCWG criteria). (lu.se)
  • The best association between OS and time-to-progression occurred with an absolute increase in aBSI equal to 0.6 (Kendall's tau 0.52). (lu.se)
  • Moreover, overexpression of this cyclin was found to be a prognostic factor determining resistance to fulvestrant and shorter progression-free survival. (lu.se)
  • It is a catch-all measurement that covers all possible reasons a person might stop therapy, including disease progression, side effects, or patient choice. (medscape.com)
  • Lim HJ , Okwera A , Mayanja-Kizza H , Ellner JJ , Mugerwa RD , Whalen CC . Effect of tuberculosis preventive therapy on HIV disease progression and survival in HIV-infected adults. (cdc.gov)
  • Girardi E , Palmieri F , Cingolani A , Ammassari A , Petrosillo N , Gillini L , Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. (cdc.gov)